Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer.
Tim WollenweberLucia ZisserElisabeth Kretschmer-ChottMichael WeberBernhard GrubmüllerGero KramerShahrokh F ShariatMarkus MitterhauserStefan SchmitlChrysoula VrakaAlexander R HaugMarcus HackerMarkus HartenbachSazan RasulPublished in: Current oncology (Toronto, Ont.) (2021)
Results evidenced no alterations in renal function and only minimal impairment of salivary function of mCRPC patients who acquired an intense PSMA-RLT regimen every 4 weeks.